دورية أكاديمية
Enhanced tolerability of the 5-hydroxytryptophane challenge test combined with granisetron
| العنوان: | Enhanced tolerability of the 5-hydroxytryptophane challenge test combined with granisetron |
|---|---|
| المؤلفون: | Jacobs, G.E., Kamerling, I.M.C., Kam, M.L. de, DeRijk, R.H., Pelt, J. van, Zitman, F.G., Gerven, J.M.A. van |
| المصدر: | Journal of Psychopharmacology |
| سنة النشر: | 2010 |
| المجموعة: | Leiden Repository (Leiden University) |
| مصطلحات موضوعية: | 5-HTP challenge test granisetron HPA-axis pharmacokinetics pharmacodynamics serotonergic function healthy-volunteers serotonin emesis nausea |
| الوصف: | A recently developed oral serotonergic challenge test consisting of 5-Hydroxytryptophane (5-HTP, 200 mg) combined with carbidopa (CBD, 100 mg + 50 mg) exhibited dose-related neuroendocrine responsiveness and predictable pharmacokinetics. However, its applicability is limited by nausea and vomiting. A randomized, double-blind, placebo-controlled, four-way crossover trial was performed in 12 healthy male volunteers. The 5-HTP/CBD-challenge was combined with two oral anti-emetics (granisetron, 2 mg or domperidone, 10 mg) to investigate its reliability when side-effects are suppressed. The neuroendocrine response (serum cortisol and prolactin), the side-effect profile [Visual Analogue Scale Nausea (VAS)] and vomiting subjects per treatment were the main outcome measures. Compared to 5-HTP/CBD/placebo, 5-HTP/CBD/granisetron had no impact on cortisol [% change with 95% confidence interval: -7.1% (18.9; 6.5)] or prolactin levels [-9.6% (-25.1; 9.1)]; 5-HTP/CBD/domperidone increased cortisol [+13.0% (-4.2; 33.4)], and increased prolactin extensively [+336.8% (245.7; 451.9)]. Compared to placebo, VAS Nausea increased non-significantly with granisetron [+7.6 mm (-1.3; 16.5)], as opposed to domperidone [+16.2 mm (7.2; 25.2)] and 5-HTP/CBD/placebo [+14.7 mm (5.5; 23.8)]. No subjects vomited with granisetron, compared to two subjects treated with 5-HTP/CBD/placebo and five subjects with domperidone. Compared with 5-HTP/CBD/placebo, granisetron addition decreased C-max of 5-HTP statistically significantly different (from 1483 to 1272 ng/ml) without influencing AUC(0-infinity). Addition of granisetron to the combined 5-HTP/CBD challenge suppresses nausea and vomiting without influencing the neuroendocrine response or pharmacokinetics, enhancing its clinical applicability in future psychiatric research and drug development. ; Stress-related psychiatric disorders across the life span |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| العلاقة: | lumc-id: 5634791; https://hdl.handle.net/1887/111548Test |
| DOI: | 10.1177/0269881108094299 |
| الإتاحة: | https://doi.org/10.1177/0269881108094299Test https://hdl.handle.net/1887/111548Test |
| رقم الانضمام: | edsbas.C3A8E556 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1177/0269881108094299 |
|---|